Abvc biopharma announces enrollment progress for adhd phase ii part 2 clinical study

Fremont, ca, june 01, 2022 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced the enrollment progress for the phase ii part 2 clinical study of the company's adhd medicine (abv-1505). since the first subject began treatment on may 10, 2022, 13 additional subjects have been enrolled in the study from a total of 23 subjects screened.
ABVC Ratings Summary
ABVC Quant Ranking